Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation
Ptpn6 is a cytoplasmic phosphatase that functions to prevent autoimmune and interleukin-1 (IL-1) receptor-dependent, caspase-1-independent inflammatory disease. Conditional deletion of Ptpn6 in neutrophils ( Ptpn6 ∆PMN ) is sufficient to initiate IL-1 receptor-dependent cutaneous inflammatory diseas...
Saved in:
Published in: | Nature immunology Vol. 21; no. 1; pp. 54 - 64 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
New York
Nature Publishing Group US
01-01-2020
Nature Publishing Group |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Ptpn6 is a cytoplasmic phosphatase that functions to prevent autoimmune and interleukin-1 (IL-1) receptor-dependent, caspase-1-independent inflammatory disease. Conditional deletion of
Ptpn6
in neutrophils (
Ptpn6
∆PMN
) is sufficient to initiate IL-1 receptor-dependent cutaneous inflammatory disease, but the source of IL-1 and the mechanisms behind IL-1 release remain unclear. Here, we investigate the mechanisms controlling IL-1α/β release from neutrophils by inhibiting caspase-8-dependent apoptosis and Ripk1–Ripk3–Mlkl-regulated necroptosis. Loss of Ripk1 accelerated disease onset, whereas combined deletion of caspase-8 and either Ripk3 or Mlkl strongly protected
Ptpn6
∆PMN
mice.
Ptpn6
∆PMN
neutrophils displayed increased p38 mitogen-activated protein kinase-dependent Ripk1-independent IL-1 and tumor necrosis factor production, and were prone to cell death. Together, these data emphasize dual functions for Ptpn6 in the negative regulation of p38 mitogen-activated protein kinase activation to control tumor necrosis factor and IL-1α/β expression, and in maintaining Ripk1 function to prevent caspase-8- and Ripk3–Mlkl-dependent cell death and concomitant IL-1α/β release.
Croker and colleagues show that the phosphatase Ptpn6 functions to suppress neutrophil cell death pathways and IL-1 release, thereby limiting autoinflammatory responses. |
---|---|
Bibliography: | Experiments: MS, AAC, JAO, AAD, ROB, JJB, RSL, MBM, IS, SW, LHC, AIS, HP, LAO, KEL, MG, BAC Funding: AWR, EW, NEL, KEL, RH, MAK, JJB, CJN, BAC Supervision: MS, AAC, JJB, EW, NEL, KEL, AWR, MG, BAC Project design: MS, AAC, JAO, AAD, JJB, RSL, MBM, IS, KEL, AIS, AWR, MG, BAC Software development: CJN Analysis: MS, CJN, AAC, JAO, ISS, PRL, AAD, ROB, JJB, RSL, MBM, IS, SW, LHC, AIS, HP, KEL, EW, NEL, AWR, MG, BAC Author Contributions Writing: MS, JAO, KEL, NEL, IS, MG, BAC |
ISSN: | 1529-2908 1529-2916 |
DOI: | 10.1038/s41590-019-0550-7 |